by Damon Race | Feb 21, 2023 | Press
February 21, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present new data from pre-clinical studies of its lead gene...
by Damon Race | Jan 23, 2023 | Press
January 23, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has expanded the Company’s management team and board of directors with the...
by Damon Race | Sep 12, 2022 | In the News
By Zac Ezzone – Staff writer, Triangle Business Journal Sep 1, 2022 A UNC-Chapel Hill spinout developing gene therapies focused on rare blood diseases and disorders has raised $1.4 million to support its efforts. The company, GeneVentiv Therapeutics, raised the...
by Damon Race | Jun 14, 2022 | In the News
The Old Well on the UNC-Chapel Hill campus. Mehmet Demirci By Zac Ezzone – Staff writer June 14, 2022, 08:52am EDT After bootstrapping for nearly two years, the CEO of a UNC-Chapel Hill spinout developing gene therapies has received some financial support. In...
by Damon Race | Jun 8, 2022 | In the News
Pixabay image by Jason Parker — June 8, 2022 RALEIGH – GeneVentiv Therapeutics, a Triangle-area pre-clinical gene therapy company, has been awarded a $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center (NCBC). The loan will enable the...
Recent Comments